Skip to main content

Advertisement

SpringerLink
Log in

Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the impact of delayed adjuvant imatinib on GIST patients with high risk of recurrence.

Method

Adult GIST patients were retrospectively collected from our hospital between 2011 and 2018, and patients having high risk of recurrence were included for subsequent analyses. The primary endpoint was recurrence-free survival (RFS).

Results

According to the interval between the radical surgery and the beginning of adjuvant imatinib, 222 patients were divided into three groups: group A (≤ 2 months, n = 41), group B (2–≤ 4 months, n = 113), and group C (4–≤ 6 months, n = 68). Univariate, multivariate, and survival analyses all showed that patients in group A had significantly more favorable RFS than those in group C but not group B, and patients taking adjuvant imatinib for over 12 months were also associated with longer RFS comparing to adjuvant imatinib of ≤ 12 months. When stratified by the duration of adjuvant imatinib, no significant differences were found in RFS among groups A, B, and C for adjuvant imatinib of ≤ 12 months. While for adjuvant imatinib of over 12 months, both groups A and B had significantly more favorable RFS than group C, and no significant difference in RFS was found between group A and B.

Conclusion

Delayed postoperative adjuvant imatinib for over 4 months in patients with high risk of recurrence of GIST may lead to worse RFS, and longer treatment with shorter delay has best results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this published article.

Code availability

Not applicable.

References

  • Bengio RM, Riva ME, Moiraghi B, Lanari E, Milone J, Ventriglia V, Bullorsky E, Tezanos Pinto M, Murro H, Bianchini M, Larripa I (2011) Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. Leuk Lymphoma 52(9):1720–1726

    Article  CAS  Google Scholar 

  • Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CDM, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008a) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625

    Article  CAS  Google Scholar 

  • Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VHC, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CDM, Crowley JJ, Borden EC (2008b) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632

    Article  CAS  Google Scholar 

  • Cavnar MJ, Seier K, Curtin C, Balachandran VP, Coit DG, Yoon SS, Crago AM, Strong VE, Tap WD, Gonen M, Antonescu CR, Brennan MF, Singer S, DeMatteo RP (2019) Outcome of 1000 patients with gastrointestinal stromal tumor (GIST) treated by surgery in the pre and post-imatinib eras. Ann Surg 273(1):128

    Article  Google Scholar 

  • DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1):51–58

    Article  CAS  Google Scholar 

  • Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, GST. American College of Surgeons Oncology Group Intergroup Adjuvant (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104

    Article  Google Scholar 

  • Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  CAS  Google Scholar 

  • Duan Y, Haybaeck J, Yang Z (2020) Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers (basel) 12(10):2972

    Article  CAS  Google Scholar 

  • Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33(5):459–465

    Article  Google Scholar 

  • Hemming ML, Heinrich MC, Bauer S, George S (2018) Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol 29(10):2037–2045

    Article  CAS  Google Scholar 

  • Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio GM, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279(5350):577–580

    Article  CAS  Google Scholar 

  • Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39(10):1411–1419

    Article  Google Scholar 

  • Joensuu H (2012) Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 9(6):351–358

    Article  Google Scholar 

  • Joensuu H, DeMatteo RP (2012) The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. Annu Rev Med 63:247–258

    Article  CAS  Google Scholar 

  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman SL, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052–1056

    Article  CAS  Google Scholar 

  • Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegard T, Reichardt P (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272

    Article  CAS  Google Scholar 

  • Joensuu H, Hohenberger P, Corless CL (2013) Gastrointestinal stromal tumour. Lancet 382(9896):973–983

    Article  CAS  Google Scholar 

  • Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schutte J, Cameron S, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S, Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegard T, Reichardt P (2020) Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up. JAMA Oncol 6(8):1241–1246

    Article  Google Scholar 

  • Khoo CY, Chai X, Quek R, Teo MCC, Goh BKP (2018) Systematic review of current prognostication systems for primary gastrointestinal stromal tumors. Eur J Surg Oncol 44(4):388–394

    Article  Google Scholar 

  • Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, Kurtovic S, Colakovic F, Kozaric M, Vranic S, Bovan NS (2016) The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. Br J Haematol 172(3):420–427

    Article  CAS  Google Scholar 

  • Kurtovic-Kozaric A, Kugic A, Hasic A, Beslija S, Ceric T, Pasic A, Vranic S, Kopric D, Iljazovic E, Todorovic Barbuscia J, Kozaric M, Ibisevic N, Keskic L, Kurtovic S (2017) Long-term outcome of GIST patients treated with delayed imatinib therapy. Eur J Cancer 78:118–121

    Article  Google Scholar 

  • Li S, Chen D, Li S, Zhao Z, Yang H, Wang D, Zhang Z, Fu W (2020) Novel prognostic nomogram for recurrence-free survival of patients with primary gastrointestinal stromal tumors after surgical resection: combination of prognostic nutritional index and basic variables. Front Oncol 10:581855

    Article  Google Scholar 

  • Liu P, Tan F, Liu H, Li B, Lei T, Zhao X (2020) The use of molecular subtypes for precision therapy of recurrent and metastatic gastrointestinal stromal tumor. Onco Targets Ther 13:2433–2447

    Article  CAS  Google Scholar 

  • Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG (2013) Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. J Med Econ 16(9):1106–1119

    Article  CAS  Google Scholar 

  • Mantese G (2019) Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Curr Opin Gastroenterol 35(6):555–559

    Article  CAS  Google Scholar 

  • Mei L, Smith SC, Faber AC, Trent J, Grossman SR, Stratakis CA, Boikos SA (2018) Gastrointestinal stromal tumors: the GIST of precision medicine. Trends Cancer 4(1):74–91

    Article  CAS  Google Scholar 

  • Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP (2018) Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: The PERSIST-5 clinical trial. JAMA Oncol 4(12):184060

    Article  Google Scholar 

  • Rutkowski P, Gronchi A (2013) Efficacy and economic value of adjuvant imatinib for gastrointestinal stromal tumors. Oncologist 18(6):689–696

    Article  CAS  Google Scholar 

  • Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wronski M, Gluszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H (2011) Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37(10):890–896

    Article  CAS  Google Scholar 

  • Serrano C, George S (2020) Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res 26(19):5078–5085

    Article  CAS  Google Scholar 

  • Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PCW, Van Glabbeke M, Bertulli R, Judson I, Grp ESTBS, Italian Sarcoma G, Australasian Gastrointestinal T (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134

    Article  CAS  Google Scholar 

  • von Mehren M, Joensuu H (2018) Gastrointestinal stromal tumors. J Clin Oncol 36(2):136

    Article  Google Scholar 

  • Zhao R, Wang Y, Huang Y, Cui Y, Xia L, Chen Y, Zhuang W, Zhou Y, Wu X (2017) Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study. Sci Rep 7(1):16834

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, 37 Guo Xue Rd., Chengdu, 610041, Sichuan Province, China

    Wan Qianyi, Zhao Rui, Wang Yong, Wu Yutao, Shen Xiaoding & Wu Xiaoting

  2. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China

    Xu Mei & Wu Yutao

Authors
  1. Wan Qianyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xu Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhao Rui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wang Yong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wu Yutao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shen Xiaoding
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wu Xiaoting
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

WQ, XM, and ZR contributed equally to this work. WX and ZR conceived together the study. All of the authors contributed to the research and development process that resulted in this article. WQ, XM, and ZR wrote the manuscript under the guidance of WX. All of the authors read the manuscript and approved the final manuscript.

Corresponding author

Correspondence to Wu Xiaoting.

Ethics declarations

Conflict of interest

There was no conflict of interest.

Ethics approval

The study was approved by the ethics committee of West China Hospital, Sichuan University. Patient records/information were anonymized and de-identified before analysis, and the methods were performed following the Declaration of Helsinki.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qianyi, W., Mei, X., Rui, Z. et al. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study. J Cancer Res Clin Oncol 148, 1493–1500 (2022). https://doi.org/10.1007/s00432-021-03749-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-021-03749-6

Keywords

Search

Navigation